News

© 2019 PHARMACOSMOS A/S
This website contains information on products which is targeted to a wide range of audiences outside US and may contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. Monofer®, CosmoFer®, Diafer® and Uniferon® are registered trademarks of Pharmacosmos A/S. All rights reserved.
Privacy Notices Terms & Conditions

Further positive results from the FERWON study programme

Jacob Tolstrup elected new Chairman of the Board of Directors of Pharmacosmos

Monoferric(TM) (iron isomaltoside 1000 for injection) receives marketing approval from Health Canada

Heavy metal impurities found in 94 percent of tested injectable irons for piglets

Pharmacosmos Introduces Pharmaceutical Quality DEAE-Dextran

Pharmacosmos Enters into Agreement with Laboratoire Aguettant for Exclusive Commercialisation Rights to Monover® (iron isomaltoside) in France

Improved animal welfare and economy: More live-born baby pigs per litter

Pharmacosmos Enters into Exclusive Commercialization Agreement with Pfizer for Monofer® (iron isomaltoside) in Brazil

Nippon Shinyaku enters into a license agreement with Pharmacosmos on an intravenous iron therapy, Monofer® (iron isomaltoside 1000)

Monofer (iron isomaltoside) launched in India under brand names “ISOFER” and “JILAZO”

Pharmacosmos to initiate large-scale clinical study programme

Pharmacosmos launches new website on novel cryoprotectant Pentaisomaltose®

First ever hard endpoint trial with IV iron (Monofer®) in chronic heart failure

Pharmacosmos Chief Medical Officer appointed Adjunct Professor

Celebrating 50 years

Pharmacosmos introduces DEAE-Dextran

Pharmacosmos Enters into Agreement with Pfizer for Exclusive Commercialization Rights in Canada to Monofer®

Media

Pharmacosmos